A mechanism of action phase 1 study showed that the glycemic efficacy of tirzepatide in T2DM results from concurrent improvements in key components of diabetes pathophysiology, including β-cell function, insulin sensitivity, and glucagon secretion (135). This evidence concerns the gene INS and diabetes mellitus.